

CA-ADAP Formulary Review: BIPOLAR DISORDER

JANUARY 17, 2024

CARRIE HOLDEN, PHARM.D

MagellanRx
MANAGEMENTSM

CA-ADAP Formulary Review: AGENDA

1 Disease Characteristics

2 Medications

3 Claims data

4 Other ADAP formularies

5 Discussion




Bipolar Disorder

BIPOLAR DISORDER



- Mental illness that causes unusual shifts in a person's mood, energy, activity levels, and concentration
 - Shifts are more severe than normal ups and downs that most people experience
- 2 main subtypes of bipolar disorder:
 - ❖ **Bipolar I Disorder**
 - Manic episodes lasting for 7+ days
 - Depressive episodes also typically occur x2 weeks
 - Episodes of depression w/mixed features
 - Rapid cycling: 4+ episodes within 1 year
 - ❖ **Bipolar II disorder**
 - A pattern of depressive and hypomanic episodes
 - No manic episodes
- BP-II is not a milder form of BP-I
 - Manic episodes of BP-I can be severe, but those with BP-II can be depressed for longer



BIPOLAR DISORDER and PLWH

- PLWH are 3-5x more likely to suffer from Bipolar Disorder than HIV negative individuals
- Mental health is a strong predictor of adherence to care
- Treatment follows the same principles as any patient, but with considerations
- General guidelines include the following:
 - Start low/titrate slow
 - Simplify dosing schedules
 - Avoid unnecessary adverse events
 - Minimize drug-drug interactions and possible end organ damage



TREATMENT of BIPOLAR DISORDER



- No cure, but appropriate treatment can decrease morbidity/mortality
- Medication selection - based on:
 - Patient preference
 - Prior response to therapy
 - Safety/tolerability
 - Anticipated side effects
 - Other medical conditions
 - Pharmacological properties



Bipolar Disorder Treatment: LITHIUM (ESKALITH, LITHOBID)



- Place in Therapy: Recommended for acute mania, acute mixed, bipolar depressive disorder, and as maintenance
 - Also used in the MDD
 - For severe mania, use w/antipsychotic; less severe mania can be monotherapy
 - Onset of anti-manic effect is seen in 5-7 days, full therapeutic effect in 10-21 days
- Common side effects: nausea, vomiting, dizziness, fatigue, drowsiness

Agent	Generic	CA ADAP FORMULARY	# Unique Cardholder ID Denials Jan - Dec 2023	AZ	CT	FL	NY	TX	WA	Comments
Lithium (ESKALITH, LITHOBID)	Y	N	31.1%	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> • Indicated for bipolar disorder and mania • Monitor 5-7 days after starting treatment, also with dose changes, until desired level reached then Q3 months • Avoid when CrCl < 30 mL/min • Dose of 300-600 mg PO BID to TID

Bipolar Disorder Treatment: ANTICONVULSTANTS



- Place in Therapy: Recommended for treatment of severe manic or mixed episodes, bipolar depressive disorder, and as maintenance treatment

Agent	Generic	CA ADAP FORMULAR Y	# Unique Cardholder ID Rx Fills or Denials* Jan – Dec 2023	AZ	CT	FL	NY	TX	WA	Comments
Carbamazepine (TEGRETOL)	Y	N	9.5%*	-	Y	-	Y	-	Y	<ul style="list-style-type: none"> • Indicated for bipolar disorder, mania, various seizure types, neuropathic pain, trig neuralgia • Numerous drug interactions w/ ART: CI with PI/c, DOR, RPV, TAF, BIC, EVG/c, RAL • Boxed warning for serious dermatologic reactions (TEN, SJS), aplastic anemia/agranulocytosis • Dose of 600 mg-1,200 mg/day in divided dose
Divalproex Sodium (DEPAKENE, DEPAKOTE)	Y	Y	5.9%	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> • Indicated for bipolar disorder, mania, various seizure types, and migraine prophylaxis • May be preferred over lithium for mixed • Contraindicated hepatic disease/impairment • Dose of 500-750 mg QD
Lamotrigine (LAMICTAL)	Y	Y	21.3%	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> • Indicated for bipolar disorder and various seizure types • Boxed warning for serious skin rashes (SJS) • Dose of 200 mg QD

Bipolar Disorder Treatment:

ATYPICAL ANTIPSYCHOTICS (2ND GENERATION)



- Place in Therapy: Recommended as **initial therapy** for most patients for the treatment of bipolar manic episodes, acute mixed episodes, and maintenance therapy
- Common side effects: weight gain and related metabolic effects, hypotension, sedation, anticholinergic symptoms, hyperprolactinemia, EPS, cardiac effects, and sexual dysfunction

Agent	Generic	CA ADAP FORMULARY	# Unique Cardholder ID Rx Fills or Denials* Jan – Dec 2023	AZ	CT	FL	NY	TX	WA	Comments
Aripiprazole (ABILIFY)	Y	Y	28.9%	Y	Y	Y	Y	-	-	<ul style="list-style-type: none"> • Indicated for bipolar disorder, mania, schizophrenia, depression, others • Dose of 10-15 mg QD (lower doses for MDD)
Asenapine (SAPHRIS)	Y	N	0.7%*	-	Y	-	-	-	-	<ul style="list-style-type: none"> • Indicated for bipolar disorder, mania, schizophrenia • Dosed 5-10mg SL BID; lower doses as adj
Cariprazine (VRAYLAR)	-	N	20.9%*	-	-	-	-	-	-	<ul style="list-style-type: none"> • Indicated for bipolar disorder, bipolar depression, mania, schizophrenia, and depression • Not recommended with severe renal or hepatic impairment • Dose of 1.5-6 mg QD
Olanzapine (ZYPREXA)	Y	Y	11.7%	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> • Indicated for bipolar disorder, bipolar depression, mania, schizophrenia, depression, and agitation • High incidence of weight gain • Dose of 10-20 mg QD

Bipolar Disorder Treatment: ATYPICAL ANTIPSYCHOTICS cont'd



Agent	Generic	CA ADAP FORMULARY	# Unique Cardholder ID Rx Fills or Denials* Jan – Dec 2023	AZ	CT	FL	NY	TX	WA	Comments
Olanzapine/ Samidorphan (LYBALVI)	N	N	1.4%*	-	-	-	-	-	-	<ul style="list-style-type: none"> Indicated for bipolar disorder and schizophrenia CI w/opioids Wt gain and prolactinemia
Quetiapine (SEROQUEL)	Y	Y	25.0%	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> Indicated for bipolar disorder, bipolar depression, mania, schizophrenia, and depression Dose of IR 150-750 mg QD
Risperidone (RISPERDAL)	Y	Y	6.7%	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> Indicated for bipolar disorder, mania, schizophrenia, and autism Dose of 2-6 mg QD
Ziprasidone (GEODON)	Y	Y	0.6%	Y	-	Y	Y	-	Y	<ul style="list-style-type: none"> Indicated for bipolar disorder, mania, schizophrenia, and agitation Dose of 40-160 mg QD

Bipolar Depression



Agent	Generic	CA ADAP FORMULARY	# Unique Cardholder ID Rx Denials Jan – Dec 2023	AZ	CT	FL	NY	TX	WA	Comments
Lumateperone (CAPLYTA)	N	N	4.1%	-	-	-	-	-	-	<ul style="list-style-type: none"> Indicated for bipolar depression and schizophrenia Dose 42 mg daily Dose titration not required
Lurasidone (LATUDA)	Y	N	32.4%	-	-	Y	-	-	-	<ul style="list-style-type: none"> Indicated for bipolar depression and schizophrenia Dose 40 mg daily (max 160 mg/day) Pregnancy Category B

Other drugs indicated for treatment of Bipolar Depression:

- Cariprazine - **VRAYLAR**
- Fluoxetine - **PROZAC**
- Olanzapine - **ZYPREXA**
- Olanzapine/Fluoxetine - **SYMBYAX**
- Quetiapine – **SEROQUEL** (adjunct)

Formulary Management Recommendations: Bipolar Disorder Treatment



1

LITHIUM
(ESKALITH, LITHOBID)

Recommend addition to the ADAP formulary

2

ANTICONVULSANTS:
CARBAMAZEPINE

Consider addition to the ADAP formulary

3

ATYPICAL
ANTIPSYCHOTICS:
CARIPRAZINE (VRAYLAR)

Consider addition to the ADAP formulary

4

LURASIDONE
(LATUDA)

Consider addition to the ADAP formulary

References



1. (No date) *Treating bipolar disorder - psychiatry*. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar-guide-1410457043063.pdf (Accessed: 28 December 2023).
2. *Bipolar disorder (2022a) Mayo Clinic*. Available at: <https://www.mayoclinic.org/diseases-conditions/bipolar-disorder/symptoms-causes/syc-20355955> (Accessed: 28 December 2023).
3. *Bipolar disorder (2022b) Mayo Clinic*. Available at: <https://www.mayoclinic.org/diseases-conditions/bipolar-disorder/symptoms-causes/syc-20355955> (Accessed: 28 December 2023).
4. *Bipolar disorder (no date) National Institute of Mental Health*. Available at: <https://www.nimh.nih.gov/health/statistics/bipolar-disorder> (Accessed: 28 December 2023).
5. de Sousa Gurgel, W. *et al.* (2013) 'Prevalence of bipolar disorder in a HIV-infected outpatient population', *AIDS Care*, 25(12), pp. 1499–1503. doi:10.1080/09540121.2013.779625.
6. Lopes, M. *et al.* (2011) 'Gender, HIV status, and psychiatric disorders', *The Journal of Clinical Psychiatry*, 73(03), pp. 384–391. doi:10.4088/jcp.10m06304.
7. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. *JAMA* 2013; 310:591.
8. U.S. Department of Veteran Affairs (VA). Depression: primary care of veterans with HIV, neurology, psychiatry, and pain. October 2011.

Confidentiality statement



By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.

The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.